ROIVW (Roivant Sciences) Altman Z2-Score: 16.44 (As of Jun. 27, 2026) — 62% Above Median


ROIVW Roivant Sciences Ltd ROIVW
55 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Altman Z2-Score?

Roivant Sciences ROIVW -3.85% 55 Altman Z2-Score is 16.44 as of Jun. 27, 2026, which is 62% above its 10-year median of 10.13. GuruFocus rates ROIVW with a GF Score™ of 55/100. The stock has 7 warning signs investors should review. Among 1,398 Biotechnology companies, Roivant Sciences ranks better than 91.13% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Roivant Sciences has a Altman Z2-Score of 16.44, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Roivant Sciences's Altman Z2-Score or its related term are showing as below:

ROIVW' s Altman Z2-Score Range Over the Past 10 Years
Min: -1.81   Med: 10.13   Max: 24.79
Current: 16.44

During the past 6 years, Roivant Sciences's highest Altman Z2-Score was 24.79. The lowest was -1.81. And the median was 10.13.


Roivant Sciences  (NAS:ROIVW) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Roivant Sciences Altman Z2-Score Related Terms


Roivant Sciences Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Altman Z2-Score Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial 2.43 -1.81 18.41 24.79 16.44

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.79 25.48 22.06 21.89 16.44

ROIVW vs INSM, INCY, BNTX: Altman Z2-Score Comparison

For the Biotechnology subindustry, Roivant Sciences's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Altman Z2-Score falls into.


ROIVW
55GF Score
Roivant Sciences Ltd ROIVW
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Roivant Sciences's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.8559+3.26*-0.0879+6.72*-0.0463+1.05*10.8759
=16.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $5,708.69 Mil.
Total Current Assets was $5,167.38 Mil.
Total Current Liabilities was $281.24 Mil.
Retained Earnings was $-501.81 Mil.
Pre-Tax Income was 454.097 + -290.369 + -159.044 + -269.262 = $-264.58 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $416.28 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5167.384 - 281.244)/5708.687
=0.8559

X2=Retained Earnings/Total Assets
=-501.814/5708.687
=-0.0879

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-264.578 - 0)/5708.687
=-0.0463

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(4527.37 - 0)/416.275
=10.8759

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Roivant Sciences has a Altman Z2-Score of 16.44 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 16.44 mean?
Roivant Sciences (ROIVW) has a Altman Z2-Score of 16.44 as of Jun. 27, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Roivant Sciences and its competitors. This is 62% above median its historical median of 10.13. According to the industry distribution chart, Roivant Sciences ranks #124 out of 1398 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Roivant Sciences' Altman Z2-Score too high?
Roivant Sciences' current Altman Z2-Score of 16.44 is 62% above median its 10-year median of 10.13. Based on the distribution chart, Roivant Sciences ranks #124 out of 1398 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Altman Z2-Score compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #124 out of 1398 companies for Altman Z2-Score. This places Roivant Sciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Altman Z2-Score is 16.44, which is 62% above median its own 10-year median of 10.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current Altman Z2-Score of 16.44. The current Altman Z2-Score is 16.44, which is 62% above median its 10-year median of 10.13. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current Altman Z2-Score is 16.44 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIVW

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price